- Home
- SAVA vs HYPR Comparison
SAVA vs HYPR Comparison
Compare SAVA & HYPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- HYPR
- Stock Information
- Founded
- SAVA 1998
- HYPR 2014
- Country
- SAVA United States
- HYPR United States
- Employees
- SAVA N/A
- HYPR N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- HYPR Medical Specialities
- Sector
- SAVA Health Care
- HYPR Health Care
- Exchange
- SAVA Nasdaq
- HYPR Nasdaq
- Market Cap
- SAVA 102.4M
- HYPR 113.9M
- IPO Year
- SAVA N/A
- HYPR N/A
- Fundamental
- Price
- SAVA $3.63
- HYPR $1.48
- Analyst Decision
- SAVA Hold
- HYPR Strong Buy
- Analyst Count
- SAVA 1
- HYPR 3
- Target Price
- SAVA $2.00
- HYPR $1.28
- AVG Volume (30 Days)
- SAVA 4.9M
- HYPR 320.7K
- Earning Date
- SAVA 11-06-2025
- HYPR 11-11-2025
- Dividend Yield
- SAVA N/A
- HYPR N/A
- EPS Growth
- SAVA N/A
- HYPR N/A
- EPS
- SAVA N/A
- HYPR N/A
- Revenue
- SAVA N/A
- HYPR $10,797,000.00
- Revenue This Year
- SAVA N/A
- HYPR $12.92
- Revenue Next Year
- SAVA N/A
- HYPR $32.10
- P/E Ratio
- SAVA N/A
- HYPR N/A
- Revenue Growth
- SAVA N/A
- HYPR N/A
- 52 Week Low
- SAVA $1.15
- HYPR $0.53
- 52 Week High
- SAVA $33.98
- HYPR $1.90
- Technical
- Relative Strength Index (RSI)
- SAVA 72.05
- HYPR 60.17
- Support Level
- SAVA $2.85
- HYPR $1.42
- Resistance Level
- SAVA $3.66
- HYPR $1.49
- Average True Range (ATR)
- SAVA 0.34
- HYPR 0.09
- MACD
- SAVA 0.10
- HYPR -0.01
- Stochastic Oscillator
- SAVA 92.90
- HYPR 61.11
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About HYPR Hyperfine Inc.
Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.